Banting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes

Diabetic Medicine

Volumn 30, Issue 3, 2013, Pages 267-275

  Taylor, R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ARGININE; FAT; GLUCOSE; GLYCOGEN; TRIACYLGLYCEROL;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; BODY MASS; BODY WEIGHT; CALORIC INTAKE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPOGENESIS; LIVER; LIVER CELL; LOW CALORY DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; REVIEW; STOMACH BYPASS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADIPOSE TISSUE; BLOOD GLUCOSE; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; GASTRIC BYPASS; HUMANS; INSULIN-SECRETING CELLS; LIVER; PANCREAS; TRIGLYCERIDES;

EID: 84874185427     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12039     Document Type: Review

References (38)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281: 2005-2012.
2. Davies NJ. Type 2 and you. Balance 2012. Available at http://www.diabetes.org.uk/How_we_help/Magazines/Balance/Past-issues/Balance/Type-2-and-you/ Last accessed 22 October 2012.
3. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
4. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007; 30: 677-682.
5. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006; 55: 1114-1120.
6. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 2004; 53: 160-165.
7. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
8. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215-2221.
9. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc Natl Acad Sci U S A 1994; 91: 10878-10882.
10. Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, et al. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 2006; 55: 1605-1613.
11. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
12. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10: S32-42.
13. Pascoe J, Hollern D, Stamateris R, Abbasi M, Romano LC, Zou B, et al. Free fatty acids block glucose-induced beta-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18. Diabetes 2012; 61: 632-641.
14. Ohneda M, Inman LR, Unger RH. Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia 1995; 38: 173-179.
15. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
16. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-608.
17. Ravikumar B, Gerrard J. Dalla Man C, Firbank MJ, Lane A, English PT et al. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 2008; 57: 2288-2295.
18. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross sectional studies in Pima Indians. N Engl J Med 1988; 318: 1217-1225.
19. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007; 104: 12587-12594.
20. Sevastianova K, Santos A, Kotronen A, Hakkarainen A, Makkonen J, Silander K et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 2012; 96: 727-734.
21. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-2277.
22. Taylor R. Pathogenesis of Type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008; 51: 1781-1789.
23. Sattar N, McConnachie A, Ford I, Gaw A, Cleland SJ, Forouhi NG, et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007; 56: 984-991.
24. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-765.
25. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54: 2506-2514.
26. Steven S, Lim EL, Taylor R. Population response to information on reversibility of Type 2 diabetes. Diabet Med 2013; doi: 10.1111/dme.12116 (Epub ahead of print).
27. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012; 35: 1420-1428.
28. Taylor R, Proctor SJ, James O, Clark F, George K, Alberti MM. The relationship between human adipocyte and monocyte insulin binding. Clin Sci (Lond) 1984; 67: 139-142.
29. Argyraki M, Wright PD, Venables CW, Proud G, Taylor R. Study of human skeletal muscle in vitro: effect of NEFA supply on glucose storage. Metabolism 1989; 38: 1183-1187.
30. Johnson AB, Argyraki M, Thoow JC, Cooper BG, Fulcher G, Taylor R. The effect of increased fatty acid supply upon glucose metabolism and skeletal muscle glycogen synthase activity in normal man. Clin Sci 1992; 82: 219-226.
31. Broughton DL, James OW, Alberti KG, Taylor R. Peripheral and hepatic insulin sensitivity in healthy elderly human subjects. Eur J Clin Invest 1991; 21: 13-21.
32. Taylor R. Resistance to injection. Diabet Med 1992; 9: 104-108.
33. Taylor R, Price TB, Rothman DL, Shulman RG, Shulman GI. Validation of 13C NMR measurement of human skeletal muscle glycogen by direct biochemical assay of needle biopsy samples. Magn Reson Med 1992; 27: 13-20.
34. Carey PE, Halliday J, Snaar JEM, Morris PG, Taylor R. Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects. Am J Physiol 2003; 284: E286-E294.
35. Singhal P, Caumo A, Carey PE, Cobelli C, Taylor R. Regulation of endogenous glucose production after a mixed meal in type 2 diabetes. Am J Physiol Endocrinol Metab 2002; 283: E275-E283.
36. Trenell MI, Hollingsworth KG, Lim EL, Taylor R. Increased daily walking improves lipid oxidation without changes in mitochondrial function in Type 2 diabetes. Diabetes Care 2008; 31: 1644-1649.
37. Chen MJ, Jovanovic A, Taylor R. Utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care 2010; 33: 2552-2554.
38. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025-2031.